Reduced referral and case fatality rates for severe symptomatic hyperlactataemia in a South African public sector antiretroviral programme: A retrospective observational study

AIDS Research and Therapy

Volumn 7, Issue , 2010, Pages

  Schutz, Charlotte ^a,b   Boulle, Andrew ^b   Stead, Dave ^a,b   Rebe, Kevin ^a,b   Osler, Meg ^b   Meintjes, Graeme ^a,b  

^a GF Jooste Hospital   (South Africa)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; BICARBONATE; LACTIC ACID; STAVUDINE; ZIDOVUDINE;

ADULT; ARTICLE; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FATALITY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLACTATEMIA; LACTATE BLOOD LEVEL; LACTIC ACIDOSIS; MAJOR CLINICAL STUDY; MALE; METABOLIC ACIDOSIS; OBSERVATIONAL STUDY; PATIENT REFERRAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SOUTH AFRICA; SYMPTOMATOLOGY;

EID: 77952640842     PISSN: 17426405     EISSN: None     Source Type: Journal    
DOI: 10.1186/1742-6405-7-13     Document Type: Article

References (17)

1. Geddes R, Knight S, Moosa MYS, Reddi A, Uebel K, Sunpath H. A high incidence of nucleoside reverse transcriptase inhibitor (NRTI)-induced lactic acidosis in HIV-infected patients in a South African context. S Afr Med J 2006, 96:722-724.
2. Stead D, Osler M, Boulle A, Rebe K, Meintjes G. Severe hyperlactataemia complicating stavudine first-line antiretroviral therapy in South Africa. Antivir Ther 2008, 13:937-943.
3. Bolhaar MG, Karstaedt AS. A high incidence of lactic acidosis and symptomatic hyperlactatemia in women receiving highly active antiretroviral therapy in Soweto, South Africa. Clin Infect Dis 2007, 45:254-260. 10.1086/518976, 17578788.
4. Songa PM, Castelnuovo B, Mugasha EB, Ocama P, Kambugu A. Symptomatic hyperlactatemia associated with nucleoside analogue reverse-transcriptase inhibitor use in HIV-infected patients: a report of 24 cases in a resource-limited setting (Uganda). Clin Infect Dis 2007, 45:514-517. 10.1086/520023, 17638205.
5. Wester CW, Okezie OA, Thomas AM, Bussmann H, Moyo S, Muzenda T, Makhema J, van Widenfelt E, Musonda R, Novitsky V, Gaolathe T, Ndwapi N, Essex M, Kuritzkes DR, deGrutolla V, Marlink RG. Higher-than-expected rates of lactic acidosis among highly active antiretroviral therapy-treated women in Botswana: preliminary results from a large randomized clinical trial. J Acquir Immune Defic Syndr 2007, 46:318-322. 10.1097/QAI.0b013e3181568e3f, 18090299.
6. Fabian J, Venter WDF, Mkhabela L, Levin JB, Baker L, Naicker S. Symptomatic hyperlactataemia in adults on antiretroviral therapy: a single-centre experience. S Afr Med J 2008, 98:795-800.
7. Manosuthi W, Prasithsirikul W, Chumpathat N, Suntisuklappon B, Athichathanabadi C, Chimsuntorn S, Sungkanuparph S. Risk factors for mortality in symptomatic hyperlactatemia among HIV-infected patients receiving antiretroviral therapy in a resource-limited setting. Int J Infect Dis 2008, 12:582-586. 10.1016/j.ijid.2007.12.005, 18337140.
8. Southern African HIV Clinicians Society Guidelines for prevention, diagnosis and management of NRTI-associated symptomatic hyperlactataemia and lactic acidosis. 2006, Southern African Journal of HIV Medicine, Southern African HIV Clinicians Society.
9. Boulle A, Orrel C, Kaplan R, Van Cutsem G, McNally M, Hilderbrand K, Myer L, Egger M, Coetzee D, Maartens G, Wood R. Substitutions due to antiretroviral toxicity or contraindication in the first 3 years of antiretroviral therapy in a large South African cohort. Antivir Ther 2007, 12:753-760.
10. Osler M, Stead D, Rebe K, Meintjes G, Boulle A. Risk factors for and clinical characteristics of severe hyperlactataemia in patients receiving antiretroviral therapy: a case-control study. HIV Medicine 2010, 11:121-129. 10.1111/j.1468-1293.2009.00754.x, 19702629.
11. Hill A, Ruxrungtham K, Hanvanich M, Katlama C, Wolf E, Soriano V, Milinkovic A, Gatell J, Ribera E. Systematic review of clinical trials evaluating low doses of stavudine as part of antiretroviral treatment. Expert Opin Pharmacother 2007, 8:679-688. 10.1517/14656566.8.5.679, 17376022.
12. Pérez EH, Dawood H, Chetty U, Esterhuizen TM, Bizaare M. Validation of the Accutrend® lactate meter for hyperlactatemia screening during antiretroviral therapy in a resource-poor setting. International Journal of Infectious Diseases 2008, 12:553-556. 10.1016/j.ijid.2008.03.007, 18511322.
13. Bekker LG, Orrell C, Reader L, Matoti K, Cohen K, Martell R, Abdullah F, Wood R. Antiretroviral therapy in a community clinic-early lessons from a pilot project. S Afr Med J 2003, 93:458-462.
14. Coetzee D, Hildebrand K, Boulle A, Maartens G, Louis F, Labatala V, Reuter H, Ntwana N, Goemaere E. Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa. AIDS 2004, 18:887-895. 10.1097/00002030-200404090-00006, 15060436.
15. Boulle A, Bock P, Osler M, Cohen K, Channing L, Hilderbrand K, Mothibi E, Zweigenthal V, Slingers N, Cloete K, Abdullah F. Antiretroviral therapy and early mortality in South Africa. Bull World Health Organ 2008, 86:678-687. 10.2471/BLT.07.045294, 2649489, 18797643.
16. South African National Department of Health National Antiretroviral Treatment Guidelines. Jacana 2004, South African National Department of Health.
17. Westreich DJ, Sanne I, Maskew M, Malope-Kgokong B, Conradie F, Majuba P, Funk MJ, Kaufman JS, Van Rie A, Macphail P. Tuberculosis treatment and risk of stavudine substitution in first-line antiretroviral therapy. Clin Infect Dis 2009, 48:1617-1623. 10.1086/598977, 2787193, 19385733.